Citadel Advisors
VYNT

Citadel Advisors’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Citadel Advisors’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-69
Closed -$41K – 8208
2017
Q2 		$41K Buy
+69
New +$40.3K ﹤0.01% 7144

Other funds holding VYNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's VYNT Position: Q1 2023 in Review

Citadel Advisors sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q1 2023, closing a stake of 11,224 shares — an estimated $7.88K sold.

Citadel Advisors first reported a position in VYNT in Q2 2016 and held it in 8 quarters. The position peaked at $97K in Q2 2021. 17 funds tracked by Wall St. Rank hold VYNT as of Q1 2023.

  • Citadel Advisors reported no remaining Vyant Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 11,224 Vyant Bio, Inc. Common Stock shares in Q1 2023, an estimated $7.88K.
  • Citadel Advisors first reported a position in Vyant Bio, Inc. Common Stock in Q2 2016 and held it in 8 quarters.
  • Citadel Advisors's Vyant Bio, Inc. Common Stock position peaked at $97K in Q2 2021.
  • 17 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.